Gland Pharma net profit declines 15 percent to Rs 232 crore in Q3
During the quarter, total R&D expense stood at Rs 51.2 crore, at 5.5 percent of revenue, the company said, adding the total capex incurred during the quarter was Rs 42.7 crore.
New Delhi: Gland Pharma Ltd on Monday reported a 15 percent decline in consolidated net profit at Rs 231.95 crore for the third quarter ended December 2022, impacted by production delays due to supply disruptions.
The company had posted a consolidated net profit of Rs 273.03 crore in the same period last fiscal, Gland Pharma said in a regulatory filing.
Consolidated revenue from operations during the quarter under review stood at Rs 938.29 crore as against Rs 1,063.33 crore in the year-ago period.
Total expenses in the third quarter were lower at Rs 688.95 crore as compared to Rs 743.43 crore in the same period a year ago.
"Challenging business environment, ongoing supply chain disruptions leading to production delays continue to impact our performance," Gland Pharma Managing Director and CEO Srinivas Sadu said.
The company's core markets US, Europe, Canada, Australia, and New Zealand accounted for 70 percent of revenue during the quarter, maintaining a similar level of revenue contribution as compared to Q3 FY22, Gland Pharma said.
Rest of the world markets contributed 21 percent while the India market accounted for 9 percent of Q3 FY23 revenue and witnessed sequential recovery of business due to normalisation of insulin production line, it added.
During the quarter, total R&D expense stood at Rs 51.2 crore, at 5.5 percent of revenue, the company said, adding the total capex incurred during the quarter was Rs 42.7 crore.
On the outlook, Sadu said the proposed acquisition of Cenexi, the company's first acquisition overseas, will enable Gland to increase its presence and expand its product and service offering capability in Europe.
"Our new production lines in our sterile facility, in Pashamylaram, will support our product portfolio of complex and differentiated delivery formats," he added
Read also: Gland Pharma to acquire 100 percent stake in Cenexi Group
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd